The effect of sodium nitroprusside on psychotic symptoms and spatial working memory in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial
- 22 September 2016
- journal article
- research article
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 46 (16) , 3443-3450
Abstract
Background: Sodium nitroprusside (SNP) has been reported to rapidly reduce psychotic symptoms in patients with schizophrenia. This has the potential to revolutionize treatment for schizophrenia. In this study, we tested the hypothesis that SNP leads to a reduction in psychotic symptoms and an improvement in spatial working memory (SWM) performance in patients with schizophrenia.Method: This was a single-centre, randomized, double-blind, placebo-controlled trial performed from 27 August 2014 to 10 February 2016 (clinicaltrials.gov identifier: NCT02176044). Twenty patients with schizophrenia aged 18–60 years with a diagnosis of schizophrenia or schizoaffective disorder were recruited from psychiatric outpatient clinics in the South London and Maudsley NHS Trust, London, UK. Baseline symptoms were measured using the Positive and Negative Syndrome Scale (PANSS) and the 18-item Brief Psychiatric Rating Scale (BPRS-18), and SWM was assessed using the CANTAB computerized test. Participants received either an infusion of SNP (0.5 μg/kg per min for 4 h) or placebo and were re-assessed for symptoms and SWM performance immediately after the infusion, and 4 weeks later.Results: SNP did not lead to any reduction in psychotic symptoms or improvement in SWM performance compared to placebo.Conclusions: Although this study was negative, it is possible that the beneficial effects of SNP may occur in patients with a shorter history of illness, or with more acute exacerbation of symptoms.Keywords
This publication has 18 references indexed in Scilit:
- Rapid Improvement of Acute Schizophrenia Symptoms After Intravenous Sodium NitroprussideJAMA Psychiatry, 2013
- Anterior Cingulate Glutamate Levels Related to Clinical Status Following Treatment in First-Episode SchizophreniaNeuropsychopharmacology, 2012
- Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia?Therapeutic Advances in Psychopharmacology, 2011
- Behavioural studies of spatial working memory dysfunction in schizophrenia: A quantitative literature reviewPsychiatry Research, 2007
- Phencyclidine affects memory in a nitric oxide-dependent manner: Working and reference memoryBehavioural Brain Research, 2006
- Blockade of phencyclidine‐induced effects by a nitric oxide donorBritish Journal of Pharmacology, 2000
- Nitric oxide modulates NMDA-induced increases in intracellular Ca2+ in cultured rat forebrain neuronsBrain Research, 1992
- Sodium nitroprusside blocks NMDA receptors via formation of ferrocyanide ionsNeuroReport, 1992
- The Positive and Negative Syndrome Scale (PANSS) for SchizophreniaSchizophrenia Bulletin, 1987
- The Brief Psychiatric Rating ScalePsychological Reports, 1962